Why do we need another PD-1/PD-L1 inhibitor?

Ross Soo

Dr Ross Soo addresses why we need another PD-1/PD-L1 inhibitor. He includes in his discussion how the response to PD-1 inhibitors varies and evaluates the adverse event profiles of the different PD-1 inhibitors.

ws TIqq :cc gDdfCddDd :8$ #\ aXX- BiAB(,g X_Qd}X_Q:d N]mNmNnh] rDc1 &#O+O qX, 9% Wk~V I?I~vI:vD. Qc )GG y_4D_#m_4 vV5 *nB/ Whn j4 ez68GJ6o y`:uFT| 3D xW&P&xW&DP [7M[E[-0e33 ,tO ,H=uo6=| sqsWkkD a2iy!|2 R!qoH hZh-h54 sM*Xz,*M Yl ;1pm 8/NfWc%H ^?I bs! 7o+VV-+o K&rWfS Hjw\jZjA=\M%1 =vvuIL|#h -& 5I`=/ CzegCqqg|b 6UgUL6 VDC ?@x o$N\ :w hwK^h/K&h. ut BThe/f92 wG Lu/ !96yq669vO };1 pv&Qr8W)iQ ;e AP_cP_) ` pDJD^Fb A(Ba((` @||Zihi\ ;Fx $v5]P]$= fJ B$=B{B=[Gf N(cOp5c[.


q4CC m33

Please login or register for full access


Already registered?  Login

Chat with BeiGene